Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin
Alpesh Amin(University of California, Irvine), Jeffrey Trocio(Pfizer (United States)), Wilson Tan(Pfizer (United States)), Kate M. O’Dell, Jack Mardekian(Pfizer (United States)), Onur Başer(STATinMED (United States)), Chad Patel, Shalabh Singhal(Integrated BioTherapeutics (United States)), Allison Keshishian(STATinMED (United States)), Lin Xie(Xi'an Jiaotong University), K Price, Priyamvada Singh, L. Vo, B Amantea(Magna Graecia University)
MEF University Institutional Repository (MEF University)
January 1, 2015
Cited by 2
Related Papers
Levosimendan for Hemodynamic Support after Cardiac Surgery
|New England Journal of Medicine|2017|299
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93
Intraoperative positive end-expiratory pressure and postoperative pulmonary complications: a patient-level meta-analysis of three randomised clinical trials
|British Journal of Anaesthesia|2022|73